Pinned post
We're building agents for autonomous science. Closed-loop, faster iterations, more discovery, less time. Massive human scientist + AI scientist collaboration.
Nick Edwards
Verified account This account is verified. Learn more@Nick___Edwards
Autonomous science. Founder and CEO at Potato (@readysetpotato). Former neuro at Brown, NIH, UCSD.
1.1K Following 1.6K Followers 2K Posts
Latest posts 5
Wow two years ago. My heart is melting
Found this by my son’s backpack. These are the momentsView quoted post on X
Everyone’s building autonomous labs. Does anyone know what data the frontier labs need?
Cell-type and pathway-specific excitation and inhibition of neural circuits has massive potential. This is inspiring!!
A major milestone for Chemogenetics. DREADD technology demonstrates therapeutic efficacy in humans.View quoted post on X
A new study published today in NEJM demonstrates preliminary safety and therapeutic benefit from DREADD-based chemogenetic treatment of refractory epilepsy, marking an extraordinary milestone for neuroscience and precision medicine.
nejm.org/doi/full/10.10…
The approach combines targeted AAV gene delivery at the epileptogenic locus with very low, subthreshold doses of clozapine to activate engineered DREADD receptors and modulate neuronal activity.
Congratulations to Bryan Roth, whose pioneering discovery of DREADDs made this field possible, and to the investigators of the NEJM study for bringing this technology to patients.
This achievement has a particularly meaningful connection to our work published in Science Magazine in 2017.
science.org/doi/10.1126/sc…
We showed that clozapine, rather than CNO itself, is the active mediator of DREADD activation in vivo and proposed that subthreshold doses of clozapine could be used to activate DREADDs in humans, anticipating a practical path toward clinical translation.
At the time, many in the scientific community viewed these findings primarily as relevant to the design of preclinical DREADD experiments. We saw a much broader opportunity, translating Chemogenetics into human therapeutics. Nearly a decade later, that vision is now becoming a reality.
Our 2017 study was supported by the research funding through the National Institutes of Health (NIH) and The National Institute on Drug Abuse (NIDA), a prime example of how fundamental basic research can ultimately enable transformative clinical applications.
This is an exciting beginning, but larger, well-controlled studies are essential to establish the magnitude and durability of therapeutic benefit and long-term safety.
Chemogenetics is moving beyond an experimental neuroscience tool toward a potentially transformative neuroscience platform. We are only beginning to realize its potential.
Whoa this is a huge deal!!
Dreadds work in humans nejm.org/doi/full/10.10…View quoted post on X
